File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The adjuvant value of Andrographis paniculata in metastatic esophageal cancer treatment - From preclinical perspectives

TitleThe adjuvant value of Andrographis paniculata in metastatic esophageal cancer treatment - From preclinical perspectives
Authors
Issue Date2017
Citation
Scientific Reports, 2017, v. 7, n. 1, article no. 854 How to Cite?
AbstractEsophageal cancer (EC) is the fourth and sixth leading cause of cancer-related deaths in China and United States, respectively. The dismal prognosis of EC is mainly attributed to distant metastases, which may not be overcome by chemotherapy alone. Hence, the use of alternative adjuvant treatments, such as herbal medicines, for metastatic EC remains a great desire of patients. Our previous study demonstrated the in vivo anti-tumor and in vitro anti-invasion activities of Andrographis paniculata (AP) in esophageal cancer. In the present study, the chemical constituents of absorbed AP components through human intestinal Caco-2 cell monolayer were verified for the first time. The anti-migratory activities and suppressive effects on metastasis-related factors such as HER2, MMP2, MMP9, TM4SF3, CXCR4 of the absorbed AP components were revealed in esophageal cancer cells EC-109. The anti-tumor and anti-metastatic effects of AP water extract (1600 mg/kg) were further confirmed in metastatic esophageal xenograft-bearing mice. Besides, AP water extract acted synergistically with cisplatin plus 5-fluorouracil on inhibiting tumor nodule growth (with combination index <0.7). Meanwhile, chemotherapeutics-induced side-effects could also be reduced by AP water extract. The present findings provide evidence on safety and advantages of the combined use of AP with chemotherapeutics in pre-clinical setting.
Persistent Identifierhttp://hdl.handle.net/10722/343238

 

DC FieldValueLanguage
dc.contributor.authorLi, Lin-
dc.contributor.authorYue, Grace Gar Lee-
dc.contributor.authorLee, Julia Kin Ming-
dc.contributor.authorWong, Eric Chun Wai-
dc.contributor.authorFung, Kwok Pui-
dc.contributor.authorYu, Jun-
dc.contributor.authorLau, Clara Bik San-
dc.contributor.authorChiu, Philip Wai Yan-
dc.date.accessioned2024-05-10T09:06:31Z-
dc.date.available2024-05-10T09:06:31Z-
dc.date.issued2017-
dc.identifier.citationScientific Reports, 2017, v. 7, n. 1, article no. 854-
dc.identifier.urihttp://hdl.handle.net/10722/343238-
dc.description.abstractEsophageal cancer (EC) is the fourth and sixth leading cause of cancer-related deaths in China and United States, respectively. The dismal prognosis of EC is mainly attributed to distant metastases, which may not be overcome by chemotherapy alone. Hence, the use of alternative adjuvant treatments, such as herbal medicines, for metastatic EC remains a great desire of patients. Our previous study demonstrated the in vivo anti-tumor and in vitro anti-invasion activities of Andrographis paniculata (AP) in esophageal cancer. In the present study, the chemical constituents of absorbed AP components through human intestinal Caco-2 cell monolayer were verified for the first time. The anti-migratory activities and suppressive effects on metastasis-related factors such as HER2, MMP2, MMP9, TM4SF3, CXCR4 of the absorbed AP components were revealed in esophageal cancer cells EC-109. The anti-tumor and anti-metastatic effects of AP water extract (1600 mg/kg) were further confirmed in metastatic esophageal xenograft-bearing mice. Besides, AP water extract acted synergistically with cisplatin plus 5-fluorouracil on inhibiting tumor nodule growth (with combination index <0.7). Meanwhile, chemotherapeutics-induced side-effects could also be reduced by AP water extract. The present findings provide evidence on safety and advantages of the combined use of AP with chemotherapeutics in pre-clinical setting.-
dc.languageeng-
dc.relation.ispartofScientific Reports-
dc.titleThe adjuvant value of Andrographis paniculata in metastatic esophageal cancer treatment - From preclinical perspectives-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/s41598-017-00934-x-
dc.identifier.pmid28405006-
dc.identifier.scopuseid_2-s2.0-85018290985-
dc.identifier.volume7-
dc.identifier.issue1-
dc.identifier.spagearticle no. 854-
dc.identifier.epagearticle no. 854-
dc.identifier.eissn2045-2322-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats